Adalimumab
- PDF / 169,480 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 67 Downloads / 156 Views
1
S
Pneumonitis: case report In multicenter, phase IV, prospective, observational study (VITALITY; NCT02451839) of 164 patients, a patient [age and sex not stated] were described, who developed severe pneumonitis during treatment with adalimumab for immune mediated inflammatory diseases (IMID). The patient, who had IMID, started receiving adalimumab [dosage and route not stated]. However, forty-eight days post initiation of adalimumab, the patient was hospitalised due to severe pneumonitis, which was considered as possibly related to adalimumab. The patient’s therapy with adalimumab was discontinued [outcome not stated]. Author comment: "Only one participant experienced an [serious adverse event] that was considered possibly related to adalimumab; this was a pneumonitis event that occurred 48 days from the start of treatment and resulted in treatment being withdrawn." Gearry RB, et al. VITALITY: impact of adalimumab on health and disability outcomes in patients with Crohn’s disease, rheumatoid arthritis, or psoriasis treated in clinical practice in New Zealand. Current Medical Research and Opinion 35: 1837-1846, No. 10, 3 Oct 2019. Available from: URL: http:// 803437024 doi.org/10.1080/03007995.2019.1634952 - New Zealand
0114-9954/19/1781-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 30 Nov 2019 No. 1781
Data Loading...
